

Substitute for form 1449/PTO (EV615581113US)				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/942,463
				Filing Date	August 29, 2001
				First Named Inventor	Nikos Panayotatos
				Art Unit	2165
				Examiner Name	Carlos A. Azpuru
Sheet 1		of	2	Attorney Docket Number	NP/1 CIP DIV 1


FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> - Number <sup>2</sup> - Kind Code <sup>3</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
<i>CA</i>		0 501 309 A1	02/09/1992	Asakawa et al.		

NON PATENT LITERATURE DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>4</sup>
<i>CA</i>		Allen, T.M., "Long-circulating (sterically stabilized) liposomes for targeted drug delivery," <i>Trends Pharm. Sci.</i> , 15(7):215-220 (1994).				
		Allen et al., "Antibody-mediated targeting of long-circulating (stealth) liposomes," <i>J. Liposome Res.</i> , 4(1):1-25 (1994).				
		Breeze et al., "Delivery of cytotoxic drugs to cancer patients using low density lipoprotein," <i>J. Controlled Release</i> , 28:321-322 (1994).				
		Citro et al., "Inhibition of leukemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligonucleotides into HL-60 cells," <i>Br. J. Cancer</i> , 69:463-467 (1994).				
		Kim et al., "Development of specific organ-targeting drug delivery system I: physico-pharmaceutical characteristics of thermally denatured albumin microspheres containing cytarabine," <i>Arch. Pharm. Res.</i> , 8(3):159-168 (1985).				
		Kramer P. A., "Albumin microspheres as vehicles for achieving specificity in drug delivery," <i>J. Pharm. Sci.</i> , 63(10):1646-1647 (1974).				
		Morimoto et al., "Drug-carrier property of albumin microspheres in chemotherapy. V. Antitumor effect of microsphere-entrapped adriamycin on liver metastasis of AH 7974 cells in rats," <i>Chem. Pharm. Bull.</i> , 29(5):1433-1438 (1981).				
		Newton D. W., "Biotechnology frontier: targeted drug delivery," <i>U.S. Pharmacist</i> , 16(4):38-39 (1991).				

Examiner Signature	<i>Carlos A. Azpuru</i>	Date Considered	<i>4/13/05</i>
-----------------------	-------------------------	--------------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol(s) as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTC/SE/CSA (03-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted in PTO 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/942,463
(use as many sheets as necessary)				Filing Date	August 29, 2001
Sheet	2	of	2	First Named Inventor	Nikos Panayotatos
				Art Unit	2165
				Examiner Name	Carlos A. Azpuru
				Attorney Docket Number	NP/1 CIP DIV 1

NON PATENT LITERATURE DOCUMENTS		
	Sugibayashi et al., "Drug-carrier property of albumin microspheres in chemotherapy. II. Preparation and tissue distribution in mice of microsphere-entrapped 5-fluorouracil," <i>Chem. Pharm. Bull.</i> , 27(1):204-209 (1979).	
	Wagner et al., "Delivery of drugs, proteins and genes into cells using transferring as a ligand for receptor-mediated endocytosis," <i>Adv. Drug Del. Rev.</i> , 14:113-135 (1994).	

Examiner Signature		Date Considered	4/13/05
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol(s) as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.